Rucotinib combined with chemotherapeutic agents can be effective in the treatment of hemophagocytic syndrome. As a class of JAK1/2 inhibitors, rucotinib can reduce the immune response, inhibit CD8+ T-cell proliferation and pro-inflammatory factor production, thus effectively prolonging the 5-year overall survival of patients with hemophagocytic syndrome. Rucotinib may or may not be combined with doxorubicin, etoposide, and dexamethasone for the treatment of lymphoma-associated phagocytic syndrome, and does not add additional toxicities. Therefore, early initiation of rucotinib in combination with chemotherapeutic agents can control the excessive inflammatory response as early as possible, buying time for subsequent lymphoma-specific treatment regimens, thereby reducing patient mortality and prolonging patient survival. Adverse reactions include myelosuppression, rash, diarrhea, etc. It is contraindicated in patients who are allergic to the product. Drugs need to be used under medical supervision, blind self-medication should be avoided.